Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Immediately Following Induction Treatment With Pemetrexed + Cisplatin for Advanced Non-squamous Non-Small Cell Lung Cancer.
Brief Summary: This study will compare progression-free survival in patients with advanced non-squamous non-small cell lung cancer. Patients who do not progress following 4 cycles of induction treatment with pemetrexed and cisplatin will be randomized 2:1 to receive either maintenance pemetrexed or placebo.


Options:
A: Arm Label: Arm A: Nivolumab + Gemcitabine + Cisplatin; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Drug: Gemcitabine, Drug: Cisplatin | Arm Label: Arm B: Nivolumab + Pemetrexed + Cisplatin; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Drug: Cisplatin, Drug: Pemetrexed | Arm Label: Arm C: Nivolumab + Paclitaxel + Carboplatin; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Drug: Paclitaxel, Drug: Carboplatin | Arm Label: Arm D: Nivolumab + Bevacizumab maintenance; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Drug: Bevacizumab | Arm Label: Arm E: Nivolumab + Erlotinib; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Drug: Erlotinib | Arm Label: Arm F: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm G: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm H: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm I: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm J: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm K: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm L: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm M: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm N: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm O: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm P: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm Q: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm R: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm S: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab + Gemcitabine + Cisplatin, Arm B: Nivolumab + Pemetrexed + Cisplatin, Arm C: Nivolumab + Paclitaxel + Carboplatin, Arm D: Nivolumab + Bevacizumab maintenance, Arm E: Nivolumab + Erlotinib, Arm F: Nivolumab, Arm G: Nivolumab + Ipilimumab, Arm H: Nivolumab + Ipilimumab, Arm I: Nivolumab + Ipilimumab, Arm J: Nivolumab + Ipilimumab, Arm K: Nivolumab, Arm L: Nivolumab, Arm M: Nivolumab, Arm N: Nivolumab + Ipilimumab, Arm O: Nivolumab + Ipilimumab, Arm P: Nivolumab + Ipilimumab, Arm Q: Nivolumab + Ipilimumab, Arm R: Nivolumab + Ipilimumab, Arm S: Nivolumab + Ipilimumab | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Arm A: Nivolumab + Gemcitabine + Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Arm A: Nivolumab + Gemcitabine + Cisplatin, Arm B: Nivolumab + Pemetrexed + Cisplatin | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Arm B: Nivolumab + Pemetrexed + Cisplatin | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm C: Nivolumab + Paclitaxel + Carboplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm C: Nivolumab + Paclitaxel + Carboplatin | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm D: Nivolumab + Bevacizumab maintenance | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): Arm E: Nivolumab + Erlotinib | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm G: Nivolumab + Ipilimumab, Arm H: Nivolumab + Ipilimumab, Arm I: Nivolumab + Ipilimumab, Arm J: Nivolumab + Ipilimumab, Arm N: Nivolumab + Ipilimumab, Arm O: Nivolumab + Ipilimumab, Arm P: Nivolumab + Ipilimumab, Arm Q: Nivolumab + Ipilimumab, Arm R: Nivolumab + Ipilimumab, Arm S: Nivolumab + Ipilimumab
B: Arm Label: pemetrexed + cisplatin followed by pemetrexed; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Cisplatin, Other: Best Supportive Care | Arm Label: pemetrexed + cisplatin followed by placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pemetrexed, Drug: Cisplatin, Drug: Placebo, Other: Best Supportive Care | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): pemetrexed + cisplatin followed by pemetrexed, pemetrexed + cisplatin followed by placebo | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): pemetrexed + cisplatin followed by pemetrexed, pemetrexed + cisplatin followed by placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): pemetrexed + cisplatin followed by placebo | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): pemetrexed + cisplatin followed by pemetrexed | Intervention Type: OTHER; Name: Best Supportive Care; Assigned to Arm(s): pemetrexed + cisplatin followed by pemetrexed, pemetrexed + cisplatin followed by placebo
C: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab | Arm Label: Arm B: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: Arm C: Nivolumab + Platinum doublet chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Carboplatin, Drug: Cisplatin, Drug: Gemcitabine, Drug: Pemetrexed, Drug: Paclitaxel | Arm Label: Arm D: Platinum doublet chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Cisplatin, Drug: Gemcitabine, Drug: Pemetrexed, Drug: Paclitaxel | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab, Arm B: Nivolumab + Ipilimumab, Arm C: Nivolumab + Platinum doublet chemotherapy | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Arm B: Nivolumab + Ipilimumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm C: Nivolumab + Platinum doublet chemotherapy, Arm D: Platinum doublet chemotherapy | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Arm C: Nivolumab + Platinum doublet chemotherapy, Arm D: Platinum doublet chemotherapy | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Arm C: Nivolumab + Platinum doublet chemotherapy, Arm D: Platinum doublet chemotherapy | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Arm C: Nivolumab + Platinum doublet chemotherapy, Arm D: Platinum doublet chemotherapy | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm C: Nivolumab + Platinum doublet chemotherapy, Arm D: Platinum doublet chemotherapy
D: Arm Label: (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Cisplatin, Drug: Gemcitabine, Drug: Pemetrexed | Arm Label: Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody; Assigned to Arm(s): Atezolizumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)

Answer: B